PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation

Asli Muvaffak(GlaxoSmithKline (United States)), Kevin Coleman(GlaxoSmithKline (United States))
Frontiers in Oncology
May 14, 2024
Cited by 8


Related Papers